GALMED PHARMACEUTICALS LTD (GLMD) Stock Analyst Ratings
USA - NASDAQ:GLMD - IL0011313900 - Common Stock
1.34 USD
-0.01 (-0.74%)
1.3252 USD
-0.01 (-1.1%)
ChartMill assigns a Buy % Consensus number of 43% to GLMD. The Buy consensus is the weighted average rating of the current analysts ratings.
GLMD was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about GLMD.
In the previous month the buy percentage consensus was at a similar level.
GLMD was analyzed by 6 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-04 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-07-24 | Maxim Group | Upgrade | Hold -> Buy |
| 2022-08-08 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-08-08 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-05-18 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2022-05-03 | Raymond James | Maintains | Outperform |
| 2022-05-03 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-05-17 | Canaccord Genuity | Maintains | Buy |
| 2021-03-19 | HC Wainwright & Co. | Maintains | Buy |
GALMED PHARMACEUTICALS LTD / GLMD FAQ
Can you provide the consensus rating for GALMED PHARMACEUTICALS LTD stock?
The consensus rating for GALMED PHARMACEUTICALS LTD (GLMD) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover GALMED PHARMACEUTICALS LTD (GLMD) stock?
The number of analysts covering GALMED PHARMACEUTICALS LTD (GLMD) is 6.